Compare Freeport-McMoRan Inc (FCX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Incyte Corporation — how do they compare? Freeport-McMoRan Inc trades at $69.18 (market cap $96.42B), while Incyte Corporation trades at $120.02 (market cap $24.54B). The key difference: Freeport-McMoRan Inc is far larger — about 3.9× Incyte Corporation's market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FCX | INCY | |
|---|---|---|
Market Cap | $96.42B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $129.93 |
52-Week Low | $35.34 | $81.61 |
Enterprise Value | $102.70B | $20.04B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $70.53, up 1.31% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust cash flow from operations highlight operational strength. The stock is near its consensus price target of $73.85, with copper market tailwinds and growth initiatives like the Grasberg ramp-up providing positive momentum.
The outlook is positive given earnings momentum and favorable copper prices, but risks include commodity price volatility and execution challenges. With a P/E of 33.76, valuation is elevated, yet growth prospects justify investor optimism. Key risks are macroeconomic sensitivity and capital expenditure demands.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
